K.J. Harrison & Partners’s Editas Medicine EDIT Stock Holding History

K.J. Harrison & Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-8,720	Closed	-$277K	–	151
2018 Q3	$277K	Hold	8,720	–	–	0.07%	161
2018 Q2	$312K	Buy	+8,720	New	+$309K	0.09%	157
2018 Q1	–	Sell	-16,020	Closed	-$492K	–	173
2017 Q4	$492K	Buy	+16,020	New	+$403K	0.17%	127

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

K.J. Harrison & Partners's EDIT Position: Q4 2018 in Review

K.J. Harrison & Partners sold out of Editas Medicine (EDIT) in Q4 2018, closing a stake of 8,720 shares — an estimated $277K sold.

K.J. Harrison & Partners first reported a position in EDIT in Q4 2017 and held it in 3 quarters. The position peaked at $492K in Q4 2017. 194 funds tracked by Wall St. Rank hold EDIT as of Q4 2018.

K.J. Harrison & Partners reported no remaining Editas Medicine position as of Q4 2018 after selling out during the quarter.
K.J. Harrison & Partners sold 8,720 Editas Medicine shares in Q4 2018, an estimated $277K.
K.J. Harrison & Partners first reported a position in Editas Medicine in Q4 2017 and held it in 3 quarters.
K.J. Harrison & Partners's Editas Medicine position peaked at $492K in Q4 2017.
194 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2018.

Based on K.J. Harrison & Partners's 13F filing for Q4 2018, filed 24 Jan 2019.